Liquid Biopsy Market Over $0.4 Billion In 2017’ Says Visiongain Report

28 August 2017
Pharma

Visiongain’s new report the Global Liquid Biopsy Market Forecast 2017-2027: Analysis of the Liquid Biopsy Market by Sample Type, Biomarker, Application and End User indicates that the global liquid biopsy market will see over $0.4bn in revenue in 2017.

The lead analyst of the report said:

“Liquid Biopsies are one of the most exciting sectors of the diagnostics market over the next decade, as increasing acceptance of liquid biopsy methods, coupled with the increase in patient comfort, using a minimally invasive technique, and the increasing aging population, with its associated increase in cancer rates, will all combine to provide perfect circumstances for growth in the market. Although the market is currently small, there will be much growth over the forecast period, leading to opportunities that can be exploited.”
The 204-page report contains 190 tables, charts and graphs that add visual analysis in order to explain developing trends within the liquid biopsy market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading liquid biopsy submarkets with 4 segmentations of the market, namely the liquid biopsy market by sample type (blood, urine, other), biomarker type (CTC, ctDNA, Exosomes), application (Lung Cancer, Gastrointestinal Cancer, Breast Cancer, Colorectal Cancer, Leukaemia, Prostate Cancer, Other cancers) and end user (Hospitals, Academic Institutes, Diagnostic Laboratories, Cancer Research Centres).

The 204-page report offers market forecasts and analysis for 5 leading regional and 19 national markets, as well as the rest of Europe, rest of Latin America, Rest of APAC and Rest of MEA markets. In addition, the report contains a dedicated leading companies’ chapter covering more than 8 companies leading the field in liquid biopsy technology.

The Global Liquid Biopsy Market Forecast 2017-2027: Analysis of the Liquid Biopsy Market by Sample Type, Biomarker, Application and End User report will be of value to anyone who wants to better understand the liquid biopsy market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the liquid biopsy industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever